island time said...
Got my 6 week post-op PSA of .01 today. What's that mean? ..........
It's my understanding that less than 1.0 is technically undetectable and below 2.0 is technically still in remission. .............................
I understand I had an ultra-sensitive test. But....wouldn't a "<.01" have been better than just a ".01"?
Do different ultra-sensitive labs report their findings differently?
I'm sure you meant < .1, not <1. So, yes, anything < 0.1 is considered undetectable by the standard PSA test. And that is the number that, when you rise above it, you may be recommended for further treatment, I think that is the standard most practitioners are still going by. Some still consider BCR(biochemical recurrence) as .2, or >.2.
But of course, if you have .01(like my last one, finally up above <0.01 to .01) it is detectable, though extremely low. So a couple of studies show that if you get to .03 or above, it is very likely that later on- who knows how long but probably with in a couple of years- you will finally reach te magic # of 0.1(ten times higher than your current) So based on the likelihood of finally having BCR(recurrence) if we ever break the .03 mark, some people are choosing to get a head start and not waiting to get all the way to .1. They are getting maybe a year or so head start.
So yes, <.01 is even better than an extremely low 0.1. But that is not very important in my mind, all that matters is your future course. So your next one may go up, or remain the same, or even go down(yes, it happens).
Also, just for general way of looking at it,
1: unlike me(G9) you have the lower risk 3+4=7, with a fairly low PSA, pretty low risk.
2: a positive margin is not huge at predicting future course of mets
3: Even if you BCR, that does not at all mean you will ever metastasize
So at least for now, accept the fact that you were .01 rather than .2 or 1 or 2 as very good news. Like the rest of us(welcome to the club LOL!) you will probably be concerned about
where it goes- if anywhere- in the future. Here is one study on how much + margins increases our risk. As I said, not huge for mets:
www.ncbi.nlm.nih.gov/pubmed/22901983Somebody said...
Abstract
BACKGROUND:
Positive surgical margins (PSMs) increase the risk of biochemical recurrence (BCR) after radical prostatectomy (RP), but their impact on hard clinical end points is a topic of ongoing discussion.
OBJECTIVE:
To evaluate the influence of solitary PSMs (sPSMs) and multiple PSMs (mPSMs) on important clinical end points.
DESIGN, SETTING, AND PARTICIPANTS:
Data from 1712 patients from the Centre Hospitalier Universitaire de Québec with pT2-4 N0 prostate cancer (PCa) and undetectable prostate-specific antigen after RP were analyzed.
INTERVENTION:
RP without neoadjuvant or adjuvant treatment...............................
RESULTS .............................
Thirteen patients (0.8%) died from PCa, and 194 patients (11.3%) died from other causes. Ten-year Kaplan-Meier estimates for BCR-free survival were 82% for margin-negative patients, 72% for patients with sPSMs, and 59% for patients with mPSMs (p<0.0001).
Time to metastatic disease, CRPC, PCa-specific mortality (PCSM), or all-cause mortality did not differ significantly among the three groups (p=0.991, p=0.988, p=0.889, and p=0.218, respectively). On multivariable analysis, sPSMs and mPSMs were associated with BCR (hazard ratio [HR]: 1.711; p=0.001 and HR: 2.075; p<0.0001), but sPSMs and mPSMs could not predict metastatic disease (p=0.705 and p=0.242), CRPC (p=0.705 and p=0.224), PCSM (p=0.972 and p=0.260), or all-cause death (p=0.102 and p=0.067). The major limitation was the retrospective design.
CONCLUSIONS:
In a cohort of patients who received early SRT in 70% of cases upon BCR, sPSMs and mPSMs predicted BCR but not long-term clinical end points. Adjuvant radiotherapy for margin-positive patients might not be justified, as only a minority of patients progressed to end points other than BCR. PCSM was exceeded 15-fold by competing risk mortality.
Post Edited (BillyBob@388) : 1/8/2016 7:33:24 PM (GMT-7)